Oncaspar Side Effects
Generic Name: pegaspargase
Note: This document contains side effect information about pegaspargase. Some of the dosage forms listed on this page may not apply to the brand name Oncaspar.
For the Consumer
Applies to pegaspargase: parenteral injection
Side effects include:
Hypersensitivity reactions, coagulopathy, hyperglycemia, elevated serum transaminase concentrations, hyperbilirubinemia, pancreatitis, CNS thrombosis. No apparent difference in adverse effects following IV versus IM administration.
For Healthcare Professionals
Applies to pegaspargase: injectable solution
General
The most commonly reported side effects were elevated transaminases and clinical allergic reactions to asparaginase (including bronchospasm, hypotension, laryngeal edema, local erythema or swelling, systemic rash, and urticaria).[Ref]
Hypersensitivity
Very common (10% or more): Hypersensitivity, urticaria, anaphylactic reaction[Ref]
Nervous system
Common (1% to 10%): Central nervous system thrombosis/hemorrhage, seizure, peripheral motor neuropathy, syncope
Rare (less than 0.1%): Posterior reversible leukoencephalopathy syndrome
Frequency not reported: Somnolence, tremor[Ref]
Cardiovascular
Common (1% to 10%): Thrombosis, embolism[Ref]
Gastrointestinal
Very common (10% or more): Pancreatitis, diarrhea, abdominal pain, nausea
Common (1% to 10%): Vomiting, stomatitis, ascites
Rare (less than 0.1%): Pancreatitis necrotizing, pancreatitis hemorrhagic
Frequency not reported: Pancreatic pseudocyst, parotitis[Ref]
Hematologic
Very common (10% or more): Febrile neutropenia
Common (1% to 10%): Coagulopathy (prolonged prothrombin time or partial thromboplastin time; or hypofibrinogenemia), anemia
Frequency not reported: Bone marrow failure[Ref]
Hepatic
Very common (10% or more): Elevated transaminases
Common (1% to 10%): Hyperbilirubinemia, hepatotoxicity, fatty liver
Rare (0.01% to 0.1%): Hepatic necrosis, jaundice, cholestasis, hepatic failure[Ref]
Metabolic
Common (1% to 10%): Hyperglycemia, weight decreased, decreased appetite
Frequency not reported: Glucose intolerance, hyperlipidemia, hypercholesterolemia, diabetic ketoacidosis, hypoglycemia[Ref]
Immunologic
Common (1% to 10%): Infections, sepsis[Ref]
Musculoskeletal
Common (1% to 10%): Pain in extremities[Ref]
Psychiatric
Frequency not reported: Confusion[Ref]
Respiratory
Common (1% to 10%): Hypoxia[Ref]
Other
Frequency not reported: Pyrexia[Ref]
Renal
Frequency not reported: Acute renal failure[Ref]
Dermatologic
Very common (10% or more): Rash
Frequency not reported: Toxic epidermal necrolysis (TEN), cerebrovascular accident, hemorrhage, superior sagittal sinus thrombosis[Ref]
References
1. "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.
Related questions
More about Oncaspar (pegaspargase)
- During Pregnancy
- Dosage Information
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: miscellaneous antineoplastics
